The performance-payout plunge was “heavily affected” by share price woes last year, which were even worse when accounting for the broader 2020 to 2022 period, Novartis said in its annual report.

In March 2022, global pharmaceutical company Novartis published its first-ever Novartis in Society integrated report. That means the company combined its report on annual financial performance ...

The global DTP vaccines market is expected to grow from $4.00 billion in 2021 to $4.45 billion in 2022 at a compound annual growth rate (CAGR) of 11.0%. The growth is mainly due to the companies ...

Basel, March 4, 2022 - Novartis shareholders today agreed to the Board of Directors' recommendations for all proposed resolutions at the Group's Annual General Meeting (AGM). In accordance with ...

Roche is forecast to tally $52.6 billion in 2022 prescription drug sales, representing a 4% annual expansion over 2015’s total of $38.7 billion, according to EvaluatePharma’s new World Preview ...